Synthon International Holdings has been granted a patent for a pharmaceutical composition containing Lenvatinib mesylate and sodium bicarbonate in specific weight ratios. The composition aims to provide a therapeutically effective dose of Lenvatinib mesylate for potential medical applications. GlobalData’s report on Synthon International Holdings gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Premium Insights Synthon International Holdings BV - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Synthon International Holdings, was a key innovation area identified from patents. Synthon International Holdings's grant share as of February 2024 was 63%. Grant share is based on the ratio of number of grants to total number of patents.

Pharmaceutical composition with lenvatinib mesylate and sodium bicarbonate

Source: United States Patent and Trademark Office (USPTO). Credit: Synthon International Holdings BV

A recently granted patent (Publication Number: US11911509B2) discloses a pharmaceutical composition containing Lenvatinib mesylate and sodium bicarbonate in specific weight ratios. The composition includes additional components such as diluents, disintegrants, and lubricants within defined ranges to enhance its therapeutic effectiveness. The patent details the preparation methods, including wet granulation and direct mix, to ensure the desired composition is achieved.

Furthermore, the patent specifies the therapeutically effective doses of Lenvatinib mesylate and sodium bicarbonate, along with the presence of microcrystalline cellulose, mannitol, and talc in the composition. The in vitro dissolution profile of the composition is also highlighted, indicating the release of at least 85% of Lenvatinib mesylate within fifteen minutes under specific conditions. The patent emphasizes the weight ratios of the components and the form of the composition, which is presented as a capsule in some instances, catering to potential pharmaceutical applications.

To know more about GlobalData’s detailed insights on Synthon International Holdings, buy the report here.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies